NeuroRx Logo.jpg
NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2/3 Trial of RLF-100 for Critical COVID-19
July 16, 2020 01:00 ET | NeuroRx
With resurgent COVID-19, enrollment has accelerated in Miami, Houston, and Irvine Data Monitoring Committee determined that so far RLF-100 has generated no drug-related Serious Adverse Events or other...
NeuroRx Logo.jpg
NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19
June 24, 2020 01:30 ET | NeuroRx
Fast Track Designation of RLF-100 for the treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome associated with COVID-19 underscores the urgent need for new treatment options for these...
NeuroRx Logo.jpg
Relief Therapeutics and NeuroRx Expand Clinical Trial Evaluating RLF-100 in Critically Ill COVID-19 Patients with Respiratory Failure to Houston Methodist Hospital
June 11, 2020 01:00 ET | NeuroRx
Clinical trial to enroll 144 patients total with expansion to additional sitesClinical trial expanded to patients treated with both noninvasive and mechanical ventilation in Critical COVID-19.RLF-100...
NeuroRx Logo.jpg
Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to All Patients with Critical COVID-19 and Respiratory Failure
June 08, 2020 01:00 ET | NeuroRx
Clinical trial expanded to patients treated with both noninvasive and mechanical ventilation in critical COVID-19Clinical trial to enroll 144 patients total with expansion to additional sites RLF-100...
NeuroRx Logo.jpg
Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF-100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress
June 01, 2020 16:03 ET | NeuroRx
First participants treated at the University of Miami Miller School of Medicine with intravenous RLF-100Clinical trial to enroll 144 patients total with expansion to additional sites including the...
Relief Therapeutics and NeuroRx Announce Final Manufacturing Validation of RLF-100 for Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress Syndrome
May 14, 2020 01:00 ET | NeuroRx
Study to enroll 144 patients with COVID-19 who have progressed to Acute Respiratory Distress and require intensive care with mechanical ventilationRLF-100 is a patented formulation of Aviptadil...